We aim to identify genetic alterations that influence cancer development, progression and therapeutic responses, in particular for prostate cancer, and further develop them into biomarkers for cancer diagnosis and therapeutic stratification, with a current focus on circulating biomarkers.
Non-invasive Detection of Clinically Significant Prostate Cancer Using Circulating Tumor Cells. J Urol (2020) 203(1):73-82. PMID: 31389764
The novel association of circulating tumor cells and circulating megakaryocytes with prostate cancer prognosis. Clin Cancer Res (2017) 23(17):5112-5122. PMID: 28615267
DNA replication-dependent induction of gene proximity by androgen. Hum Mol Genet (2015) 15;24(4):963-71. PMID: 25281662
Identification of ZDHHC14 as a novel human tumour suppressor gene. J Pathol (2014) 232(5):566-77. PMID: 24407904
I have set up a research team devoted to cancer genetic studies and biomarker development, in particular in male urological cancers. The mission of the research team is to reduce mortality and morbidity of cancer patients by understanding cancer development and progression mechanisms and facilitating precision medicine through the development of efficient cancer detection, prognostic and treatment response prediction/monitoring biomarkers.
Our past work has been mainly focused on identification of genetic alterations and genetic mechanisms in cancer development, progression and therapeutic response. Recently, our research work moved into circulation biomarker development, including CTCs, exosome and other cells, for cancer diagnosis, prognosis and prediction/monitoring of cancer progression and therapeutic response.
There are currently two main research areas of interest:
Discovery and validation of bladder cancer related excreted nucleosides biomarkers by dilution approach in cell culture supernatant and urine using UHPLC-MS/MS Chang Q, Chen P, Yin J et al. Journal of Proteomics (2023) 270(7)
Hsa_circ_0094606 promotes malignant progression of prostate cancer by inducing M2 polarization of macrophages through PRMT1-mediated arginine methylation of ILF3. Zhang Y, Wang K, Yang D et al. Carcinogenesis (2022) (2)
Rare Germline Variants Are Associated with Rapid Biochemical Recurrence After Radical Prostate Cancer Treatment: A Pan Prostate Cancer Group Study Burns D, Anokian E, Saunders EJ et al. European Urology (2022) 82(7) 201-211
Prostate cancer risk stratification improvement across multiple ancestries with new polygenic hazard score. Huynh-Le M-P, Karunamuni R, Fan CC et al. Prostate Cancer Prostatic Dis (2022) 25(2) 755-761
Assessing the causal role of epigenetic clocks in the development of multiple cancers: a Mendelian randomization study. Morales Berstein F, McCartney DL, Lu AT et al. Elife (2022) 11(2)
Investigating the Fibrillar Ultrastructure and Mechanics in Keloid Scars Using In Situ Synchrotron X-ray Nanomechanical Imaging. Zhang Y, Hollis D, Ross R et al. Materials (Basel) (2022) 15(1)
The interaction of p53 and DNA repair gene mutations and their impact on tumor mutation burden and immune response in human malignancies. Xue X, Dong L, Burke E et al. Am J Cancer Res (2022) 12(2) 1866-1883
Polygenic hazard score is associated with prostate cancer in multi-ethnic populations Huynh-Le MP, Fan CC, Karunamuni R et al. Nature Communications (2021) 12(7)
Facile One-Pot Nanoproteomics for Label-Free Proteome Profiling of 50-1000 Mammalian Cells Martin K, Zhang T, Lin TT et al. Journal of Proteome Research (2021) 20(7) 4452-4461
A Novel CpG Methylation Risk Indicator for Predicting Prognosis in Bladder Cancer Guo Y, Yin J, Dai Y et al. Frontiers in Cell and Developmental Biology (2021) 9(7)For additional publications, please click here
Clinical Research Fellows